Folate-coated, long-circulating and pH-sensitive liposomes enhance doxorubicin antitumor effect in a breast cancer animal model.
Animals
Antineoplastic Agents
/ pharmacology
Breast Neoplasms
/ diagnostic imaging
Cell Line, Tumor
Cell Survival
/ drug effects
Disease Models, Animal
Doxorubicin
/ blood
Female
Folic Acid
/ chemistry
Hydrogen-Ion Concentration
Liposomes
Mice, Inbred BALB C
Neoplasm Metastasis
Tissue Distribution
/ drug effects
Breast cancer
Cardiotoxicity
Doxorubicin
Folic acid
Long-circulating liposome
pH-Sensitive liposome
Journal
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
ISSN: 1950-6007
Titre abrégé: Biomed Pharmacother
Pays: France
ID NLM: 8213295
Informations de publication
Date de publication:
Oct 2019
Oct 2019
Historique:
received:
19
06
2019
revised:
23
07
2019
accepted:
26
07
2019
pubmed:
11
8
2019
medline:
6
2
2020
entrez:
11
8
2019
Statut:
ppublish
Résumé
Long circulating pH-sensitive liposomes have been shown to effectively deliver doxorubicin (DOX) to tumors and reduce its toxic effects. Folic acid receptors are upregulated in a wide variety of solid, epithelial tumors, including breast cancer. In order to improve liposomal endocytosis and antitumor activity, folic acid has been added to nanoparticles surfaces to exploit overexpression of folate receptors in tumor cells. The purpose of this study was to evaluate the antitumor activity in vitro and in vivo of long circulating pH-sensitive folate-coated DOX-loaded liposomes (SpHL-DOX-Fol) in a 4T1 breast cancer model system in vitro and in vivo. Biodistribution studies were performed and in vivo electrocardiographic parameters were evaluated. A higher tumor uptake for radiolabeled SpHL-Fol (
Identifiants
pubmed: 31400669
pii: S0753-3322(19)32977-4
doi: 10.1016/j.biopha.2019.109323
pmc: PMC7104811
mid: NIHMS1571193
pii:
doi:
Substances chimiques
Antineoplastic Agents
0
Liposomes
0
Doxorubicin
80168379AG
Folic Acid
935E97BOY8
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
109323Subventions
Organisme : NIGMS NIH HHS
ID : P20 GM103542
Pays : United States
Organisme : NCRR NIH HHS
ID : P20 RR024485
Pays : United States
Informations de copyright
Copyright © 2019 The Authors. Published by Elsevier Masson SAS.. All rights reserved.
Références
Clin Cancer Res. 2000 May;6(5):1949-57
pubmed: 10815920
Drug Res (Stuttg). 2016 Jun;66(6):330-6
pubmed: 27022719
J Mol Biol. 1965 Aug;13(1):238-52
pubmed: 5859039
Arch Toxicol. 2016 Sep;90(9):2063-2076
pubmed: 27342245
Toxicol Appl Pharmacol. 2018 Aug 1;352:162-169
pubmed: 29864484
Colloids Surf B Biointerfaces. 2019 Jan 1;173:539-548
pubmed: 30343218
Biomed Pharmacother. 2019 Jan;109:1728-1739
pubmed: 30551427
J Control Release. 2018 Oct 10;287:194-215
pubmed: 30165140
Int J Pharm. 2014 Jun 5;467(1-2):123-38
pubmed: 24680951
Eur J Pharm Biopharm. 2016 Aug;105:40-9
pubmed: 27264717
Drug Metab Pers Ther. 2019 Feb 1;34(1):
pubmed: 30707682
J Intern Med. 1999 Apr;245(4):359-64
pubmed: 10356598
Colloids Surf B Biointerfaces. 2015 Dec 1;136:553-61
pubmed: 26454545
Int J Exp Pathol. 2007 Oct;88(5):351-60
pubmed: 17877537
J Control Release. 2019 Feb 28;296:1-13
pubmed: 30615983
Colloids Surf B Biointerfaces. 2018 Oct 1;170:514-520
pubmed: 29960952
Nanomedicine. 2017 Jul;13(5):1693-1701
pubmed: 28343016
Nanoscale. 2017 Nov 9;9(43):17063-17073
pubmed: 29085938
J Biomed Nanotechnol. 2015 Feb;11(2):342-50
pubmed: 26349310
J Control Release. 2016 Nov 10;241:45-56
pubmed: 27639681
Small. 2018 Mar;14(13):e1703968
pubmed: 29430825
J Biomed Nanotechnol. 2013 Sep;9(9):1636-43
pubmed: 23980511
Int J Nanomedicine. 2012;7:5259-69
pubmed: 23091378
Nanoscale Res Lett. 2018 Nov 3;13(1):350
pubmed: 30392055
Biomed Pharmacother. 2018 Jul;103:1348-1354
pubmed: 29864917
CA Cancer J Clin. 2019 Jan;69(1):7-34
pubmed: 30620402
Drug Deliv Transl Res. 2018 Oct;8(5):1483-1507
pubmed: 29978332
Mol Imaging Biol. 2016 Dec;18(6):898-904
pubmed: 27172938
J Colloid Interface Sci. 2016 Feb 1;463:279-87
pubmed: 26550786
ACS Appl Mater Interfaces. 2017 Mar 22;9(11):9315-9326
pubmed: 28244731
Int J Oncol. 2018 Jan;52(1):103-126
pubmed: 29115583
Langmuir. 2018 May 22;34(20):5728-5737
pubmed: 29676924
J Struct Biol. 2018 Apr;202(1):61-69
pubmed: 29277356
Biomed Pharmacother. 2018 Jan;97:489-495
pubmed: 29091899
J Control Release. 2017 Oct 28;264:228-236
pubmed: 28844758
Int J Nanomedicine. 2017 Jul 14;12:5053-5067
pubmed: 28765708
Mol Pharm. 2018 Apr 2;15(4):1618-1626
pubmed: 29498868
Colloids Surf B Biointerfaces. 2018 Oct 1;170:718-728
pubmed: 30005409
Breast Cancer (Dove Med Press). 2018 Sep 11;10:131-141
pubmed: 30237735
Med Sci Monit. 2000 Mar-Apr;6(2):411-20
pubmed: 11208348
Biomed Pharmacother. 2017 May;89:268-275
pubmed: 28235689
PLoS One. 2018 May 3;13(5):e0196763
pubmed: 29723224
Biomed Res Int. 2013;2013:467147
pubmed: 23984367
Biophys Chem. 2000 Oct 30;87(2-3):127-37
pubmed: 11099176
Theranostics. 2017 Jan 1;7(2):319-328
pubmed: 28042337
Nanomedicine. 2018 Apr 19;14(4):1407-1416
pubmed: 29680672
Nat Protoc. 2006;1(3):1112-6
pubmed: 17406391
Int J Nanomedicine. 2016 Aug 09;11:3737-51
pubmed: 27563241
Biophys J. 1992 Apr;61(4):902-10
pubmed: 1581503